Valuation : Mylan N.V.

Market Cap 18.96B 16.36B 15.39B 14.02B 26.36B 1,800B 26.5B 182B 70.8B 915B 71.2B 69.65B 3,036B P/E 2026 *
78.4x
P/E 2027 * 31.1x
Enterprise Value 31.03B 26.77B 25.18B 22.94B 43.13B 2,945B 43.37B 298B 116B 1,498B 116B 114B 4,967B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 2x
Free-Float
91.44%
Yield 2026 *
3.08%
Yield 2027 * 3.16%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 18.96B
+0.60%-5.80%+58.06%+108.59% 1,031B
+1.73%-1.12%+51.67%+68.29% 641B
+1.88%-1.87%+23.08%+76.00% 453B
-1.50%-7.04%+33.55%+33.94% 349B
+6.25%+2.04%+28.97%+46.57% 290B
-0.07%-4.12%+0.95%+11.79% 252B
+1.76%-1.31%+52.11%+70.01% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+1.87%+0.21%+32.26%+94.49% 181B
Average +1.40%-2.98%+29.02%+50.54% 403.31B
Weighted average by Cap. +1.21%-3.97%+37.97%+66.35%

Financials

2026 *2027 *
Net sales 14.78B 12.75B 11.99B 10.93B 20.55B 1,403B 20.66B 142B 55.19B 714B 55.5B 54.3B 2,366B 15.03B 12.96B 12.19B 11.11B 20.89B 1,426B 21B 144B 56.11B 726B 56.42B 55.2B 2,406B
Net income -27.26M -23.51M -22.12M -20.15M -37.89M -2.59B -38.1M -261M -102M -1.32B -102M -100M -4.36B 340M 293M 276M 251M 472M 32.26B 475M 3.26B 1.27B 16.41B 1.28B 1.25B 54.4B
Net Debt 12.07B 10.41B 9.79B 8.92B 16.77B 1,145B 16.86B 116B 45.05B 582B 45.3B 44.32B 1,931B 11.08B 9.56B 8.99B 8.19B 15.4B 1,051B 15.48B 106B 41.36B 535B 41.6B 40.69B 1,773B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-